<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the efficacy and toxicity of topotecan-based combined chemotherapy for refractory or <z:e sem="disease" ids="C1335737" disease_type="Neoplastic Process" abbrv="">relapsed hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Twenty-one patients with refractory or relapsed <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (AL), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) or high risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were treated by topotecan with <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="2687">amsacrine</z:chebi> or <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received a single course as salvage therapy </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The overall response rate of one course was 61.9% with 9/21 (42.9%) CR and 4/21 (19%) PR </plain></SENT>
<SENT sid="4" pm="."><plain>Severe <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> was observed in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Agranulocytic time was 12.6 days in AL and 7.5 days in NHL </plain></SENT>
<SENT sid="6" pm="."><plain>Sixteen of 21 patients received G-CSF 300 micro g/d <z:hpo ids='HP_0000001'>All</z:hpo> patients received supportive treatment of transfusion </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001945'>Fever</z:hpo> and documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> developed in 15 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Non-hematologic toxicity was mild </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Topotecan-based combined chemotherapy has significant antitumour activity and acceptable toxicity as salvage therapy for high risk <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
</text></document>